Stockscreener 앱 받기
1,065.00
2.24%
23.35
시간 외 거래:
1064.59
-0.41
-0.04%
Lilly Eli Co 주식(LLY)의 최신 뉴스
Eli Lilly weight loss drug data supports long-term obesity market position, says UBS - Proactive Investors
Eli Lilly (LLY) Reports Promising Results for Verve-102 in Heart-2 Study - GuruFocus
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia - PR Newswire
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. - The Motley Fool
Eli Lilly Weight-Loss Drug Retatrutide Posts Impressive Data; Can Novo Nordisk Break Through After Falling Behind Again? - TradingKey
Inside Biotech: Lilly’s retatrutide raises the bar again in the obesity drug race - Proactive financial news
Patients on Lilly's next-gen obesity drug lost 28% of body weight, company says - AOL.com
CNBC Reports Strong Phase 3 Results for Eli Lilly’s Retatrutide - Insider Monkey
Mounjaro and the U.S. obesity market: what matters now - AD HOC NEWS
Eli Lilly New Drug Just Matched Bariatric Surgery Results. Why Did the Stock Barely Move? - TIKR.com
Eli Lilly stock (US5324571083): trillion?dollar weight?loss giant in focus after powerful run - AD HOC NEWS
Next-gen obesity drug helps patients lose 28% of body weight: Eli Lilly - NewsNation
COGIC responds after Eli Lilly files lawsuit over drug reimbursements - WSMV
Eli Lilly & Co Surges on Powerful Pipeline Hopes - TipRanks
Lilly: $202 Million Acquisition Of Genetic Medicines Company Engage Bio - Pulse 2.0
Eli Lilly (LLY) Announces Positive Phase 3 Results for Obesity Treatment Retatrutide - Insider Monkey
Inside Makary’s ouster; Another win for Lilly’s triple-G; and more - Endpoints News
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Lilly goes on $21B buying spree to build drug pipeline - Indianapolis Business Journal
Eli Lilly Highlights Positive Late-Stage Foundayo Data At Obesity Conference - Benzinga
LLY: Eli Lilly's Retatrutide Achieves Key Milestone in Phase III Trials - GuruFocus
Novo Nordisk faces new GLP-1 rival as Eli Lilly's triple agonist sets weight-loss record - Yahoo! Finance Canada
Eli Lilly Surge Puts S&P 500 Value Test In Focus - Kalkine Media
Eli Lilly Stock (LLY) Opinions on GLP-1 Drug Expansions - Quiver Quantitative
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,250 to $1,400 - 富途牛牛
Experimental Drug Yields Dramatic Weight Loss - The New York Times
Eli Lilly (LLY) GLP-1 Drugs Show Promise in Cancer Treatment - GuruFocus
Ritatrutide Shows Promising Weight Loss Results, Boosting Eli Li - GuruFocus
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,280 - Moomoo
Obesity is your fault - The Telegraph
Eli Lilly's next-generation obesity treatment "retatrutide" has ignited competition for next-generat.. - 매일경제
Eli Lilly's Retatrutide Shows 28% Weight Loss in Phase 3 Trial - 조선일보
Eli Lilly Sues COGIC Leaders Over Alleged $200 Million Drug Rebate Scheme - Christianity Today
Eli Lilly Raises $8.9 Billion in Debt Offering - The Globe and Mail
Why is Eli Lilly stock rallying today? By Investing.com - Investing.com Nigeria
Lilly to present oncology data at 2026 ASCO meeting By Investing.com - Investing.com Canada
Eli Lilly’s new weight-loss injection showed jaw-dropping results in study - Deseret News
Lilly accuses church-linked pharmacies, wholesalers and more of running $200M+ rebate fraud scheme - Fierce Pharma
New obesity drug from Lilly delivers major weight loss - The Hill
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss - Benzinga
A next-generation drug causes dramatic weight loss. Here’s how much. - CTV News
Eli Lilly (LLY) Sees Strong Growth Driven by Mounjaro Momentum and GLP-1 Demand, Barclays Remains Bullish - Insider Monkey
New weight-loss shot appears to outperform other obesity drugs on market - The Guardian
Retatrutide, Eli Lilly's next obesity drug, fueled dramatic weight loss in clinical trial - LiveNOW from FOX
Engage Bio acquired by Lilly - The Pharma Letter
Eli Lilly (LLY) Reports Promising Weight Loss Results for Retatr - GuruFocus
A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says - Time Magazine
Eli Lilly’s (LLY) Next-Generation Weight-Loss Drug Clears Big Hurdle - TipRanks
How does Lilly’s next-gen obesity drug compare to Novo’s (LLY) - Seeking Alpha
Another Triumph: Lilly’s triple G agonist scores in obesity - BioWorld News
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story? - Yahoo! Finance Canada
Where will all the workers park? Upper Macungie planners have questions about Lilly construction - The Morning Call
Eli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now? - The Globe and Mail
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and PfizerGlobal Forecast to 2030 and 2035 - Yahoo Finance UK
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial - statnews.com
Eli Lilly acquires Engage Biologics for up to $202 million - qz.com
Eli Lilly (LLY) Achieves Groundbreaking Weight Loss Results in P - GuruFocus
Eli Lilly (LLY) Maintains Buy Rating with $1,281 Price Target Fo - GuruFocus
1.13%
1.43%
자본화:
|
볼륨(24시간):